Pipeline

BioEclipse Therapeuticss™ Is Working To Transform Cancer Therapies From Treatment to Cures

Cancer Has Multiple Causes and Challenges That Requires a Multi-Mechanistic Approach

CRX100, currently in Phase1b, represents the potential to engineer an immune response in the solid tumor microenvironment 1) at the level of activation of the innate immune system, previously undruggable, and 2) with subsequent immune targeting of specific disease processes in a full adaptive immune response. Thus, overcoming resistance and reducing cancer recurrence. The safe and dependable activation of the innate immune response has been illusive until now. BioEclipse’s Immunotherapeutics precisely initiate the appropriate innate immune response to modulate cells of the adaptive immune system. These cells can then recognize a variety of tumor cell molecules and attack those tumor cells.  The patient’s endogenous antitumor immune cells are required for the long-term durability of the adaptive immune antitumor response.

CRX-100

Allogeneic CRX200 IND Ready | Autologous CRX100 Phase 1b

Autologous-Allogeneic

Our low-cost allogeneic CRX200 offers superior advantages including 1) saving patients the burden of apheresis that all other cell therapies require at each infusion, 2) delivers more potent tumor killing per infusion thus reducing the number of infusions, and 3) lowers the dose of cells and payload.

 

Our allogeneic CRX200 have been de-risked by achieving in autologous phase 1 clinical trial through regulatory, manufacturing and cold chain shipping milestones.

Clinical Trials

BioEclipse Therapeutics is in Phase 1b Trials With Our First-in-Class Medicine For Difficult-To-Treat Ovarian Cancer Patients.

 

IND Ready Proprietary Platform Targeting Solid Tumors CRX200

 

Link to clinicaltrials.gov

 

In general there are multiple challenges for refractory and resistant solid Malignancies. Challenges for Ovarian cancer specifically are that Patients are often first identified at an advanced stage of disease with 85% that become resistant to Standard of Care (SOC), 15% enter treatment already resistant to platinum drugs. Immunotherapies including CRX200 are promising as more effective treatments, especially if moved to first line or second line treatment.

Differentiation of CAR-T vs CRX-100

CAR-T-vs-CRX-100

Scientific References

Scientific references
  1. Jiang JT, Shen YP, Wu CP, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010;16(48):6155-6162. doi:10.3748/wjg.v16.i48.6155 [PubMed]

 

  1. Bartlett, D. A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection. Available from: https://clinicaltrials.gov/ct2/show/NCT00574977. NCT Identifier: NCT00574977 Last Update: December 25, 2015 [ClinicalTrials.gov]

 

  1. Chalikonda S, Kivlen MH, O’Malley ME, et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008;15(2):115-125. doi:10.1038/sj.cgt.7701110 [PubMed]

 

  1. Contag CH, Sikorski R, Negrin RS, et al. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res. 2010;70(23):9837-9845. doi:10.1158/0008-5472.CAN-10-2650 [PubMed]

 

  1. Downs-Canner S, Guo ZS, Ravindranathan R, et al. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther. 2016;24(8):1492-1501. doi:10.1038/mt.2016.101 [PubMed]
  1. Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1679-1687. doi:10.1016/j.bbmt.2011.05.012 [PubMed]

 

  1. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11(3):181-187. doi:10.1016/j.bbmt.2004.11.019 [PubMed]

 

  1. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751-8757 [PubMed]

 

  1. Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112(6):2563-2574. doi:10.1182/blood-2007-06-092817 [PubMed]

 

  1. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther. 2013;21(3):620-628. doi:10.1038/mt.2012.257 [PubMed]

 

  1. Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015;141(5):839-849. doi:10.1007/s00432-014-1864-3 [PubMed]

 

  1. Thorne SH, Liang W, Sampath P, et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther. 2010;18(9):1698-1705. doi:10.1038/mt.2010.140 [PubMed]

 

  1. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311(5768):1780-1784. doi:10.1126/science.1121411 [PubMed]